Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27728086 | 0.87 | LMNA (0.68) | POLBALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL12793245 | 0.86 | POLB (0.88) | POLBALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL3341489 | 0.84 | USP2 (0.68) | POLBALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL22217089 | 0.84 | USP2 (0.62) | POLBALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL7903516 | 0.83 | POLB (0.67) | POLBALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL4050436 | 0.83 | POLB (0.67) | POLBALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL8724926 | 0.83 | POLB (0.67) | POLBALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL15231957 | 0.83 | POLB (0.67) | POLBALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL7904262 | 0.83 | ALDH1A1 (0.70) | POLBALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL5018987 | 0.83 | USP2 (0.71) | POLBALDH1A1LMNAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023023156-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| US-11225491-B2 | Thiazolo-pyrimidine HIV-1 reverse transcriptase inhibitor, preparation method therefor, and uses thereof | SHAN DONG UNIVERSITY (CN) | 2022-01-18 | — | — | US | disclosed |
| US-20200361959-A1 | THIAZOLO-PYRIMIDINE HIV-1 REVERSE TRANSCRIPTASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | SHAN DONG UNIVERSITY (CN) | 2020-11-19 | — | — | US | disclosed |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2020-07-23 | — | — | US | disclosed |
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2020-07-21 | — | — | US | disclosed |
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1368327-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-6656932-B2 | Treating osteoarthritis, rheumatoid arthritis, cancer, inflammation, and heart failure | WARNER-LAMBERT COMPANY | 2003-12-02 | — | — | US | disclosed |
| EP-1362054-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | disclosed |
| WO-2002064599-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064578-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-1993013079-A1 | ANTIFOLATE QUINAZOLINES | AGOURON PHARMACEUTICALS, INC. (US) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | POLB 966/4885ALDH1A1 812/4885LMNA 1210/4885 |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | MMP15, MMP13, MMP3 | POLB 3288/4885ALDH1A1 399/4885LMNA 3858/4885 |
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | POLB 1548/4885ALDH1A1 133/4885LMNA 2856/4885 |
| US-11225491-B2 | Thiazolo-pyrimidine HIV-1 reverse transcriptase inhibitor, preparation method therefor, and uses thereof | TYMP, TYMS, DPYD | POLB 138/4885ALDH1A1 200/4885LMNA 3931/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | POLB 1756/4885ALDH1A1 1096/4885LMNA 2785/4885 |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | POLB 1756/4885ALDH1A1 1096/4885LMNA 2785/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | POLB 1756/4885ALDH1A1 1096/4885LMNA 2785/4885 |
| US-20200361959-A1 | THIAZOLO-PYRIMIDINE HIV-1 REVERSE TRANSCRIPTASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | TYMP, TYMS, DPYD | POLB 138/4885ALDH1A1 200/4885LMNA 3931/4885 |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | POLB 1548/4885ALDH1A1 133/4885LMNA 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.